Melas Syndrome (mitochondrial Encephalomyopathy, lactic acidosis (see [Metabolism[/mechanisms/[insulin-resistance-ad[/mechanisms/[insulin-resistance-ad[/mechanisms/[insulin-resistance-ad--TEMP--/mechanisms)--FIX--), And [Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX-- Like Episodes) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
MELAS (mitochondrial Encephalomyopathy, lactic acidosis (see [Metabolism[/mechanisms/[insulin-resistance-ad[/mechanisms/[insulin-resistance-ad[/mechanisms/[insulin-resistance-ad--TEMP--/mechanisms)--FIX--), and [Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX---like episodes (see [[Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX--[/diseases/[[Stroke[/diseases/[stroke[/diseases/[[Stroke--TEMP--/diseases/stroke[//diseases//diseases/[stroke--TEMP--//diseases//diseases/[Stroke[//diseases//diseases//diseases/[stroke--TEMP--//diseases//diseases/[Stroke[//diseases//diseases//diseases/[stroke](//diseases//diseases/stroke](//diseases//diseases/[Stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/[Stroke](/diseases//diseases//diseases//diseases/stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/stroke](//diseases//diseases/[Stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/Stroke (//diseases//diseases)--FIX-- (/diseases//diseases/stroke) ()--FIX-- (/diseases/stroke) ()--FIX--))) is a rare, maternally inherited mitochondrial disorder that predominantly affects the nervous system and muscles. First described by Pavlakis et al. in 1984, MELAS is one of the most common and well-characterized mitochondrial diseases, with an estimated incidence of approximately 1 in 4,000 live births 1(https://www.ncbi.nlm.nih.gov/books/NBK532959/). The condition is caused by point mutations in mitochondrial DNA (mtDNA (see [mitochondrial Dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics--TEMP--/entities)--FIX--)), most commonly the m.3243A>G mutation in the MT-TL1 (mitochondrial tRNA^Leu) gene encoding mitochondrial tRNALeu(UUR), which is present in approximately 80% of affected individuals 2(https://pmc.ncbi.nlm.nih.gov/articles/PMC9582660/).
MELAS belongs to the broader group of [mitochondrial diseases] and shares features with other mitochondrial syndromes. The hallmark of the disease is the occurrence of [Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX---like episodes (see [[Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX--[/diseases/[[Stroke[/diseases/[stroke[/diseases/[[Stroke--TEMP--/diseases/stroke[//diseases//diseases/[stroke--TEMP--//diseases//diseases/[Stroke[//diseases//diseases//diseases/[stroke--TEMP--//diseases//diseases/[Stroke[//diseases//diseases//diseases/[stroke](//diseases//diseases/stroke](//diseases//diseases/[Stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/[Stroke](/diseases//diseases//diseases//diseases/stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/stroke](//diseases//diseases/[Stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/Stroke (//diseases//diseases)--FIX-- (/diseases//diseases/stroke) ()--FIX-- (/diseases/stroke) ()--FIX--)) (SLEs) that typically begin between ages 2 and 40, leading to progressive neurological disability. Unlike ischemic strokes, these episodes do not conform to vascular territories and are thought to result from mitochondrial angiopathy and impaired energy metabolism in the brain 3(https://www.mdpi.com/2218-273X/14/12/1524).
Population prevalence studies have estimated the carrier frequency of the m.3243A>G mutation to be remarkably high — approximately 1 in 400 in some populations — though only a fraction of carriers develop the full MELAS phenotype. In Northern England, the prevalence of this variant in the adult population has been determined to be approximately 1 per 13,000 4(https://pubmed.ncbi.nlm.nih.gov/17300999/).
¶ Genetics and Molecular Basis
MELAS is caused by pathogenic variants in mitochondrial DNA (mtDNA (see [mitochondrial Dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics--TEMP--/entities)--FIX--)), which is maternally inherited. The mitochondrial genome is a 16,569-base pair circular molecule encoding 13 proteins of the respiratory chain, 22 tRNAs, and 2 rRNAs.
- m.3243A>G (MT-TL1 (mitochondrial tRNA^Leu)): The most common causative mutation, accounting for approximately 80% of MELAS cases. This A-to-G transition at nucleotide position 3243 affects the mitochondrial tRNALeu(UUR) gene, impairing mitochondrial protein synthesis and [Oxidative Phosphorylation[/mechanisms/[mitochondrial-dysfunction-ad[/mechanisms/[mitochondrial-dysfunction-ad[/mechanisms/[mitochondrial-dysfunction-ad--TEMP--/mechanisms)--FIX-- 2(https://pmc.ncbi.nlm.nih.gov/articles/PMC9582660/).
- m.3271T>C (MT-TL1 (mitochondrial tRNA^Leu)): The second most common mutation, responsible for approximately 10% of cases. This T-to-C substitution also affects the tRNALeu(UUR) gene 1(https://www.ncbi.nlm.nih.gov/books/NBK532959/).
- Other mutations: Additional pathogenic variants have been identified in MT-TL1 (mitochondrial tRNA^Leu) (m.3252A>G), MT-ND5 (NADH dehydrogenase subunit 5) (m.13513G>A, m.13514A>G), MT-ND1, MT-ND3, MT-ND4, and MT-TF genes, though these are less frequent 5(https://www.ncbi.nlm.nih.gov/books/NBK1233/).
¶ Heteroplasmy and Threshold Effect
A critical concept in MELAS pathogenesis is heteroplasmy — the coexistence of mutant and wild-type mtDNA (see [mitochondrial Dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics--TEMP--/entities)--FIX--) molecules within the same cell. Since each cell contains hundreds to thousands of mitochondria, each with multiple copies of mtDNA (see [mitochondrial Dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics--TEMP--/entities)--FIX--), the proportion of mutant mtDNA (see [mitochondrial Dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics--TEMP--/entities)--FIX--) varies between tissues and individuals 2(https://pmc.ncbi.nlm.nih.gov/articles/PMC9582660/).
- The threshold effect dictates that clinical manifestations appear only when the proportion of mutant mtDNA (see [mitochondrial Dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics--TEMP--/entities)--FIX--) exceeds a tissue-specific threshold, typically 60–90% for the m.3243A>G mutation.
- Mitotic segregation during cell division can alter the proportion of mutant mtDNA (see [mitochondrial Dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics--TEMP--/entities)--FIX--) in daughter cells, contributing to phenotypic variability even within families.
- Higher mutant loads in muscle and brain tissue correlate with more severe neurological and myopathic symptoms.
MELAS follows a maternal (mitochondrial) inheritance pattern. Children can only inherit mtDNA (see [mitochondrial Dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics--TEMP--/entities)--FIX--) mutations from their mother, as sperm mitochondria are eliminated after fertilization. However, due to the mitochondrial bottleneck during oogenesis, the proportion of mutant mtDNA (see [mitochondrial Dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics--TEMP--/entities)--FIX--) transmitted to offspring can vary dramatically, making genetic counseling challenging 5(https://www.ncbi.nlm.nih.gov/books/NBK1233/).
The pathogenesis of MELAS involves multiple interacting mechanisms that collectively explain the diverse clinical manifestations:
The primary defect in MELAS is impaired mitochondrial protein synthesis resulting from dysfunctional tRNALeu(UUR). This leads to:
- Reduced assembly and function of respiratory chain complexes, particularly Complex I (see [Mitochondrial Dysfunction[/mechanisms/[mitochondrial-dysfunction-ad[/mechanisms/[mitochondrial-dysfunction-ad[/mechanisms/[mitochondrial-dysfunction-ad--TEMP--/mechanisms)--FIX--) (NADH:ubiquinone oxidoreductase) and Complex IV (see [Mitochondrial Dysfunction[/mechanisms/[mitochondrial-dysfunction-ad[/mechanisms/[mitochondrial-dysfunction-ad[/mechanisms/[mitochondrial-dysfunction-ad--TEMP--/mechanisms)--FIX--) (cytochrome c oxidase) 3(https://www.mdpi.com/2218-273X/14/12/1524).
- Deficient [Oxidative Phosphorylation[/mechanisms/[mitochondrial-dysfunction-ad[/mechanisms/[mitochondrial-dysfunction-ad[/mechanisms/[mitochondrial-dysfunction-ad--TEMP--/mechanisms)--FIX-- and decreased ATP production.
- Compensatory shift toward anaerobic glycolysis, resulting in elevated lactate levels (lactic acidosis (see [Metabolism[/mechanisms/[insulin-resistance-ad[/mechanisms/[insulin-resistance-ad[/mechanisms/[insulin-resistance-ad--TEMP--/mechanisms)--FIX--)).
- Proliferation of abnormal [mitochondria] in affected tissues, visible as ragged-red fibers on muscle biopsy.
A distinctive feature of MELAS pathophysiology is the involvement of small blood vessels:
- mitochondrial proliferation occurs in the smooth muscle and endothelial cells of cerebral arterioles and capillaries 6(https://pubmed.ncbi.nlm.nih.gov/26095523/).
- This angiopathy leads to impaired vasodilation and blood perfusion, contributing to [Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX---like episodes (see [[Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX--[/diseases/[[Stroke[/diseases/[stroke[/diseases/[[Stroke--TEMP--/diseases/stroke[//diseases//diseases/[stroke--TEMP--//diseases//diseases/[Stroke[//diseases//diseases//diseases/[stroke--TEMP--//diseases//diseases/[Stroke[//diseases//diseases//diseases/[stroke](//diseases//diseases/stroke](//diseases//diseases/[Stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/[Stroke](/diseases//diseases//diseases//diseases/stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/stroke](//diseases//diseases/[Stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/Stroke (//diseases//diseases)--FIX-- (/diseases//diseases/stroke) ()--FIX-- (/diseases/stroke) ()--FIX--)).
- Affected vessels show strongly SDH-reactive (succinate dehydrogenase) walls on histochemistry.
[Nitric oxide] (NO) plays a crucial role in MELAS pathophysiology:
- Impaired Complex I (see [Mitochondrial Dysfunction[/mechanisms/[mitochondrial-dysfunction-ad[/mechanisms/[mitochondrial-dysfunction-ad[/mechanisms/[mitochondrial-dysfunction-ad--TEMP--/mechanisms)--FIX--) function leads to decreased NADH oxidation and increased NADH/NAD+ ratio.
- Elevated lactate consumes NO through chemical reactions, while arginine (the NO precursor) becomes depleted.
- NO deficiency impairs vasodilation, exacerbating ischemia during [Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX---like episodes (see [[Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX--[/diseases/[[Stroke[/diseases/[stroke[/diseases/[[Stroke--TEMP--/diseases/stroke[//diseases//diseases/[stroke--TEMP--//diseases//diseases/[Stroke[//diseases//diseases//diseases/[stroke--TEMP--//diseases//diseases/[Stroke[//diseases//diseases//diseases/[stroke](//diseases//diseases/stroke](//diseases//diseases/[Stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/[Stroke](/diseases//diseases//diseases//diseases/stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/stroke](//diseases//diseases/[Stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/Stroke (//diseases//diseases)--FIX-- (/diseases//diseases/stroke) ()--FIX-- (/diseases/stroke) ()--FIX--)).
- This mechanism provides the rationale for L-arginine supplementation therapy 3(https://www.mdpi.com/2218-273X/14/12/1524).
Dysfunctional respiratory chain complexes generate excess [[reactive oxygen species[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- ([ROS[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX--, leading to:
- Oxidative damage to mtDNA (see [mitochondrial Dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics--TEMP--/entities)--FIX--), further impairing mitochondrial function in a vicious cycle.
- Damage to cellular membranes, proteins, and nuclear DNA.
- Activation of [apoptotic pathways[/entities/[apoptosis[/entities/[apoptosis[/entities/[apoptosis--TEMP--/entities)--FIX-- and [neuronal death[/entities/[apoptosis[/entities/[apoptosis[/entities/[apoptosis--TEMP--/entities)--FIX--.
MELAS is a multisystem disorder with highly variable clinical presentation. Symptoms typically appear in childhood or early adulthood after a period of normal early development.
- [Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX---like episodes (see [[Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX--[/diseases/[[Stroke[/diseases/[stroke[/diseases/[[Stroke--TEMP--/diseases/stroke[//diseases//diseases/[stroke--TEMP--//diseases//diseases/[Stroke[//diseases//diseases//diseases/[stroke--TEMP--//diseases//diseases/[Stroke[//diseases//diseases//diseases/[stroke](//diseases//diseases/stroke](//diseases//diseases/[Stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/[Stroke](/diseases//diseases//diseases//diseases/stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/stroke](//diseases//diseases/[Stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/Stroke (//diseases//diseases)--FIX-- (/diseases//diseases/stroke) ()--FIX-- (/diseases/stroke) ()--FIX--)) (SLEs): The hallmark of MELAS, typically occurring before age 40. [Episodes present with acute focal neurological deficits including hemiparesis, hemianopia, or cortical blindness. Unlike ischemic strokes, SLEs do not follow vascular territories and preferentially affect the parietal and occipital lobes (see [Cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/cortex--TEMP--/brain-regions)--FIX--) 1(.
- lactic acidosis (see [Metabolism[/mechanisms/[insulin-resistance-ad[/mechanisms/[insulin-resistance-ad[/mechanisms/[insulin-resistance-ad--TEMP--/mechanisms)--FIX--): Elevated blood and cerebrospinal fluid lactate levels, reflecting impaired oxidative metabolism.
- Encephalopathy: Recurrent [episodes of altered consciousness[/diseases/[epilepsy[/diseases/[epilepsy[/diseases/[epilepsy--TEMP--/diseases)--FIX--, cognitive decline, and progressive dementia.
- Myopathy: Proximal muscle weakness, exercise intolerance, and easy fatigability.
- [seizures[/diseases/[epilepsy[/diseases/[epilepsy[/diseases/[epilepsy--TEMP--/diseases)--FIX--: Focal or generalized [seizures[/diseases/[epilepsy[/diseases/[epilepsy[/diseases/[epilepsy--TEMP--/diseases)--FIX-- occur in approximately 70–90% of patients, often associated with [Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX---like episodes (see [[Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX--[/diseases/[[Stroke[/diseases/[stroke[/diseases/[[Stroke--TEMP--/diseases/stroke[//diseases//diseases/[stroke--TEMP--//diseases//diseases/[Stroke[//diseases//diseases//diseases/[stroke--TEMP--//diseases//diseases/[Stroke[//diseases//diseases//diseases/[stroke](//diseases//diseases/stroke](//diseases//diseases/[Stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/[Stroke](/diseases//diseases//diseases//diseases/stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/stroke](//diseases//diseases/[Stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/Stroke (//diseases//diseases)--FIX-- (/diseases//diseases/stroke) ()--FIX-- (/diseases/stroke) ()--FIX--)) 5(https://www.ncbi.nlm.nih.gov/books/NBK1233/).
- Migraine-like headaches: Severe, recurrent headaches with visual aura.
- Cerebellar ataxia: Progressive difficulty with coordination and balance.
- Cognitive impairment: Progressive decline in executive function, memory, and language.
- Peripheral neuropathy: Sensorimotor neuropathy affecting the extremities.
- Sensorineural hearing loss: Present in 50–75% of patients.
- [[diabetes[/diseases/[diabetes[/diseases/[diabetes[/diseases/[diabetes--TEMP--/diseases)--FIX--[/diseases/[[diabetes[/diseases/[diabetes[/diseases/[[diabetes--TEMP--/diseases/diabetes[//diseases//diseases/[diabetes--TEMP--//diseases//diseases/[diabetes[//diseases//diseases//diseases/[diabetes--TEMP--//diseases//diseases/[diabetes[//diseases//diseases//diseases/[diabetes](//diseases//diseases/diabetes](//diseases//diseases/[diabetes](//diseases//diseases//diseases/diabetes](//diseases//diseases/[diabetes](/diseases//diseases//diseases//diseases/diabetes](//diseases//diseases//diseases/diabetes](//diseases//diseases/diabetes](//diseases//diseases/[diabetes](//diseases//diseases//diseases/diabetes](//diseases//diseases/diabetes (//diseases//diseases)--FIX-- (/diseases//diseases/diabetes) ()--FIX-- (/diseases/diabetes) ()--FIX--): Occurs in approximately 20–30% of patients with m.3243A>G.
- Short stature: Growth retardation is common, particularly with childhood onset.
- Cardiac involvement: Cardiomyopathy (hypertrophic or dilated), Wolff-[Parkinson]-White syndrome, and conduction defects.
- Ophthalmological findings: Pigmentary retinopathy, optic atrophy, and external ophthalmoplegia.
- Gastrointestinal dysfunction: Nausea, vomiting, intestinal pseudo-obstruction.
- Renal tubular dysfunction: Proximal tubular acidosis, focal segmental glomerulosclerosis.
The Hirano criteria (1992) and subsequent modifications require:
- [Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX---like episodes (see [[Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX--[/diseases/[[Stroke[/diseases/[stroke[/diseases/[[Stroke--TEMP--/diseases/stroke[//diseases//diseases/[stroke--TEMP--//diseases//diseases/[Stroke[//diseases//diseases//diseases/[stroke--TEMP--//diseases//diseases/[Stroke[//diseases//diseases//diseases/[stroke](//diseases//diseases/stroke](//diseases//diseases/[Stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/[Stroke](/diseases//diseases//diseases//diseases/stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/stroke](//diseases//diseases/[Stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/Stroke (//diseases//diseases)--FIX-- (/diseases//diseases/stroke) ()--FIX-- (/diseases/stroke) ()--FIX--)) before age 40.
- Encephalopathy with [seizures[/diseases/[epilepsy[/diseases/[epilepsy[/diseases/[epilepsy--TEMP--/diseases)--FIX--, dementia, or both.
- mitochondrial myopathy with lactic acidosis (see [Metabolism[/mechanisms/[insulin-resistance-ad[/mechanisms/[insulin-resistance-ad[/mechanisms/[insulin-resistance-ad--TEMP--/mechanisms)--FIX--), ragged-red fibers, or both.
- At least two of: normal early development, recurrent headache, recurrent vomiting 1(.
- Elevated serum/CSF lactate: A hallmark finding, though not always present at rest.
- Elevated serum/CSF lactate-to-pyruvate ratio: Suggests mitochondrial dysfunction.
- Elevated creatine kinase: Indicative of myopathy.
- Urine organic acids: May show elevated Krebs cycle intermediates.
- Brain MRI: [Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX---like lesions not confined to vascular territories, often in the parietal-occipital regions. Signal abnormalities on T2/FLAIR imaging. Progressive cortical and subcortical atrophy. [basal ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia--TEMP--/brain-regions)--FIX-- calcifications may be present 3(https://www.mdpi.com/2218-273X/14/12/1524).
- MR spectroscopy: Elevated lactate peak; reduced N-acetylaspartate (NAA).
- CT: May show [basal ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia--TEMP--/brain-regions)--FIX-- calcifications.
- Blood leukocyte DNA: Initial testing for m.3243A>G in MT-TL1 (mitochondrial tRNA^Leu); sensitivity is approximately 80% but may underestimate mutant load due to selection against mutant mtDNA (see [mitochondrial Dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics--TEMP--/entities)--FIX--) in blood 5(https://www.ncbi.nlm.nih.gov/books/NBK1233/).
- Urine sediment DNA: More reliable for detecting the m.3243A>G mutation due to higher heteroplasmy levels in urinary epithelial cells.
- Muscle biopsy DNA: Gold standard for quantifying heteroplasmy. Also reveals ragged-red fibers (modified Gomori trichrome) and COX-negative/SDH-positive fibers.
¶ Treatment and Management
There is currently no curative therapy for MELAS. Management is multidisciplinary and focuses on symptom mitigation, prevention of metabolic crises, and slowing disease progression.
- L-Arginine: Intravenous L-arginine (0.5 g/kg) during acute [Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX---like episodes (see [[Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX--[/diseases/[[Stroke[/diseases/[stroke[/diseases/[[Stroke--TEMP--/diseases/stroke[//diseases//diseases/[stroke--TEMP--//diseases//diseases/[Stroke[//diseases//diseases//diseases/[stroke--TEMP--//diseases//diseases/[Stroke[//diseases//diseases//diseases/[stroke](//diseases//diseases/stroke](//diseases//diseases/[Stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/[Stroke](/diseases//diseases//diseases//diseases/stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/stroke](//diseases//diseases/[Stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/Stroke (//diseases//diseases)--FIX-- (/diseases//diseases/stroke) ()--FIX-- (/diseases/stroke) ()--FIX--)) improves symptoms by enhancing NO synthesis and vasodilation. Oral arginine (0.15–0.3 g/kg/day) is used for prophylaxis 3(https://www.mdpi.com/2218-273X/14/12/1524).
- L-Citrulline: An alternative NO precursor with better oral bioavailability, showing promising results in clinical studies.
- Seizure management: Anti-seizure medications (levetiracetam, lacosamide preferred; valproic acid is contraindicated as it inhibits mitochondrial function).
- Supportive care: Hydration, electrolyte correction, avoidance of metabolic stressors.
- Coenzyme Q10 (CoQ10): Supplementation (200–400 mg/day) to support electron transport chain function and provide antioxidant protection.
- High-dose taurine: Oral taurine (9–12 g/day) has shown efficacy in preventing [Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX---like episodes (see [[Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX--[/diseases/[[Stroke[/diseases/[stroke[/diseases/[[Stroke--TEMP--/diseases/stroke[//diseases//diseases/[stroke--TEMP--//diseases//diseases/[Stroke[//diseases//diseases//diseases/[stroke--TEMP--//diseases//diseases/[Stroke[//diseases//diseases//diseases/[stroke](//diseases//diseases/stroke](//diseases//diseases/[Stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/[Stroke](/diseases//diseases//diseases//diseases/stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/stroke](//diseases//diseases/[Stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/Stroke (//diseases//diseases)--FIX-- (/diseases//diseases/stroke) ()--FIX-- (/diseases/stroke) ()--FIX--)) in a randomized controlled trial, possibly by improving mitochondrial tRNA modification 7(https://rarediseases.org/rare-/diseases/melas-syndrome/).
- B-vitamin supplementation: Riboflavin (vitamin B2) as a cofactor for Complex I (see [Mitochondrial Dysfunction[/mechanisms/[mitochondrial-dysfunction-ad[/mechanisms/[mitochondrial-dysfunction-ad[/mechanisms/[mitochondrial-dysfunction-ad--TEMP--/mechanisms)--FIX--) and II; thiamine for pyruvate dehydrogenase support.
- L-Carnitine: To support fatty acid metabolism and buffer toxic acyl-CoA species.
- Exercise therapy: Moderate aerobic exercise to stimulate mitochondrial biogenesis.
- Dietary management: Avoidance of fasting; some patients benefit from a high-fat, low-carbohydrate diet.
- mitochondrial replacement therapy (MRT): Techniques such as pronuclear transfer and maternal spindle transfer to prevent maternal transmission of mtDNA (see [mitochondrial Dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics--TEMP--/entities)--FIX--) mutations 7(https://rarediseases.org/rare-/diseases/melas-syndrome/).
- Gene therapy: Approaches under investigation include allotopic expression of mitochondrial genes and mitochondrial-targeted nucleases to selectively eliminate mutant mtDNA (see [mitochondrial Dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics--TEMP--/entities)--FIX--).
- mitochondrial transplantation: Experimental approaches to introduce healthy mitochondria into affected tissues.
- Elamipretide (SS-31): A mitochondrial-targeted peptide that stabilizes cardiolipin and improves respiratory chain function, under investigation in clinical trials.
MELAS carries a significant disease burden with progressive neurological decline:
- [Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX---like episodes (see [[Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX--[/diseases/[[Stroke[/diseases/[stroke[/diseases/[[Stroke--TEMP--/diseases/stroke[//diseases//diseases/[stroke--TEMP--//diseases//diseases/[Stroke[//diseases//diseases//diseases/[stroke--TEMP--//diseases//diseases/[Stroke[//diseases//diseases//diseases/[stroke](//diseases//diseases/stroke](//diseases//diseases/[Stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/[Stroke](/diseases//diseases//diseases//diseases/stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/stroke](//diseases//diseases/[Stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/Stroke (//diseases//diseases)--FIX-- (/diseases//diseases/stroke) ()--FIX-- (/diseases/stroke) ()--FIX--)) tend to recur and accumulate, leading to progressive hemiparesis, cortical blindness, and cognitive deterioration.
- Life expectancy varies widely but is significantly reduced. Many patients die in childhood or young adulthood, though some with lower heteroplasmy levels survive into their 40s–60s.
- Causes of death include status epilepticus, respiratory failure, cardiac complications, and severe metabolic crises.
- The m.3243A>G mutation is associated with a spectrum of phenotypes beyond MELAS, including maternally inherited [diabetes[/diseases/[diabetes[/diseases/[diabetes[/diseases/[diabetes--TEMP--/diseases)--FIX-- and deafness (MIDD) and chronic progressive external ophthalmoplegia (CPEO), depending on heteroplasmy levels and tissue distribution.
MELAS syndrome shares features with other mitochondrial disorders. See also:
- [MERRF (Myoclonic Epilepsy with Ragged-Red Fibers[/diseases/[merrf[/diseases/[merrf[/diseases/[merrf--TEMP--/diseases)--FIX-- — Another common mitochondrial syndrome featuring myoclonus, seizures, and ragged-red fibers
- [POLG-Related Mitochondrial Disorders[/diseases/[polg-related-mitochondrial-disorders[/diseases/[polg-related-mitochondrial-disorders[/diseases/[polg-related-mitochondrial-disorders--TEMP--/diseases)--FIX-- — Including Alpers-Huttenlocher syndrome
- [Friedreich Ataxia[/diseases/[friedreich-ataxia[/diseases/[friedreich-ataxia[/diseases/[friedreich-ataxia--TEMP--/diseases)--FIX-- — A frataxin-related mitochondrial disorder
- [Kearns-Sayre Syndrome[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases — Mitochondrial deletion syndrome with external ophthalmoplegia
- [All Diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases
The study of Melas Syndrome (mitochondrial Encephalomyopathy, lactic acidosis (see [Metabolism[/mechanisms/[insulin-resistance-ad[/mechanisms/[insulin-resistance-ad[/mechanisms/[insulin-resistance-ad--TEMP--/mechanisms)--FIX--), And [Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX-- Like Episodes) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [El-Hattab AW, Adesina AM, Jones J, Scaglia F. MELAS Syndrome)
- [Chen T, et al. Pathogenic mitochondrial DNA 3243A>G mutation: From genetics to phenotype)
- [Chiarelli N, et al. [Diagnosis and Management of mitochondrial Encephalopathy, lactic acidosis (see [Metabolism[/mechanisms/[insulin-resistance-ad[/mechanisms/[insulin-resistance-ad[/mechanisms/[insulin-resistance-ad--TEMP--/mechanisms)--FIX--), and [Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX---like episodes (see [[Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX--[/diseases/[[Stroke[/diseases/[stroke[/diseases/[[Stroke--TEMP--/diseases/stroke[//diseases//diseases/[stroke--TEMP--//diseases//diseases/[Stroke[//diseases//diseases//diseases/[stroke--TEMP--//diseases//diseases/[Stroke[//diseases//diseases//diseases/[stroke](//diseases//diseases/stroke](//diseases//diseases/[Stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/[Stroke](/diseases//diseases//diseases//diseases/stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/stroke](//diseases//diseases/[Stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/Stroke (//diseases//diseases)--FIX-- (/diseases//diseases/stroke) ()--FIX-- (/diseases/stroke) ()--FIX--)) Syndrome)(https://www.mdpi.com/2218-273X/14/12/1524)
- [Majamaa K, et al. [Population prevalence of the MELAS A3243G mutation)(https://pubmed.ncbi.nlm.nih.gov/17300999/)
- [DiMauro S, Hirano M. [MELAS)(https://www.ncbi.nlm.nih.gov/books/NBK1233/)
- [El-Hattab AW, et al. [MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options)(https://pubmed.ncbi.nlm.nih.gov/26095523/)
- [NORD. [MELAS Syndrome)(https://rarediseases.org/rare-/diseases/melas-syndrome/)
- [Cleveland Clinic. [MELAS Syndrome: What It Is, Causes, Symptoms & Treatment)]https://my.clevelandclinic.org/[health))
- [MedlinePlus. [mitochondrial encephalomyopathy, lactic acidosis (see [Metabolism[/mechanisms/[insulin-resistance-ad[/mechanisms/[insulin-resistance-ad[/mechanisms/[insulin-resistance-ad--TEMP--/mechanisms)--FIX--), and [Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX---like episodes (see [[Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX--[/diseases/[[Stroke[/diseases/[stroke[/diseases/[[Stroke--TEMP--/diseases/stroke[//diseases//diseases/[stroke--TEMP--//diseases//diseases/[Stroke[//diseases//diseases//diseases/[stroke--TEMP--//diseases//diseases/[Stroke[//diseases//diseases//diseases/[stroke](//diseases//diseases/stroke](//diseases//diseases/[Stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/[Stroke](/diseases//diseases//diseases//diseases/stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/stroke](//diseases//diseases/[Stroke](//diseases//diseases//diseases/stroke](//diseases//diseases/Stroke (//diseases//diseases)--FIX-- (/diseases//diseases/stroke) ()--FIX-- (/diseases/stroke) ()--FIX--)))(https://medlineplus.gov/genetics/condition/mitochondrial-encephalomyopathy-lactic-acidosis-and-[Stroke[/diseases/[stroke[/diseases/[stroke[/diseases/[stroke--TEMP--/diseases)--FIX---like-episodes/)
- [UMDF. [MELAS)(https://umdf.org/melas/)